Premium
Peri‐operative oral triiodothyronine replacement therapy to prevent postoperative low triiodothyronine state following valvular heart surgery
Author(s) -
Choi Y. S.,
Kwak Y. L.,
Kim J. C.,
Chun D. H.,
Hong S. W.,
Shim J. K.
Publication year - 2009
Publication title -
anaesthesia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.839
H-Index - 117
eISSN - 1365-2044
pISSN - 0003-2409
DOI - 10.1111/j.1365-2044.2009.05984.x
Subject(s) - medicine , placebo , triiodothyronine , anesthesia , cardiopulmonary bypass , vasopressin , placebo group , cardiac surgery , surgery , hormone , alternative medicine , pathology
Summary This study evaluated the effect of oral triiodothyronine (T 3 ) replacement therapy, starting on the day of the surgery, on thyroid hormone concentrations and clinical outcome in high‐risk patients undergoing valvular heart surgery. Fifty patients were randomly allocated to either T 3 or placebo. In the treatment (T 3 ) group patients received 20 μg of oral or nasogastric T 3 every 12 h starting just before induction of anaesthesia and until the first day after surgery. T 3 concentrations were significantly higher in the T 3 group than the placebo group from 1 to 36 h after removal of the aortic cross clamp. The number of patients requiring vasopressin after discontinuing cardiopulmonary bypass was significantly greater in the placebo group than the T 3 group. Significantly fewer patients required vasopressors in the T 3 group on the first day after surgery.